glp 1 and substance use disorder GLP-1 receptor agonists show promise in treating disorders GLP-1s Reduced Risk of Developing

& Colina, R

10.1074/jbc.270.25.14843

Therefore, we investigated whether ISF with lower dose enhances GLP-1 secretion in DIO mice

doi:10.1002/art.21139 Meissner WG, Remy P, Giordana C, et al

Clinical trials show semaglutide can cause small increases in resting heart rate, and the Wegovy SmPC lists 'heart rate increased' as an adverse reaction, though individual experiences vary considerably

Individuals were excluded if they met any of the following criteria: chronic liver disease other than NAFLD, including alcohol, viral, drug-induced, autoimmune and genetic diseases, liver cirrhosis, or clinical diagnosis of hepatic decompensation (such as oesophageal varices or ascites)